

TRADEMARK ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release of Security Interest		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
King Pharmaceuticals Research and Development, Inc.		05/11/2010	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	CREDIT SUISSE AG		
Street Address:	11 Madison Avenue		
Internal Address:	As Administrative Agent		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10010		
Entity Type:	Bank: SWITZERLAND		
PROPERTY NUMBERS Total: 41			
Property Type	Number	Word Mark	
Registration Number:	1473847	ADENOCARD	
Registration Number:	1816335	ADENOSCAN	
Registration Number:	1541189	ADENOSCAN	
Registration Number:	1812659	ALTACE	
Registration Number:	2669786	AVINZA	
Registration Number:	3319329	AVINZA	
Registration Number:	1600325	CHLOROSTAT	
Registration Number:	1040408	CORGARD	
Registration Number:	1170890	CORZIDE	
Registration Number:	2167335	CYTOMEL	
Registration Number:	3049183	DP	
Registration Number:	1742709	DP	
Registration Number:	1810413		

OP \$1040.00 1473847

900161931

TRADEMARK
REEL: 004204 FRAME: 0021

Registration Number:	2016089	LEVOXYL
Registration Number:	2158841	
Registration Number:	1657982	LIQUI-CHAR
Registration Number:	0874778	PULMONAIRE
Registration Number:	3362798	REMOXY
Registration Number:	0926416	SILVADENE
Registration Number:	1020307	SILVADENE
Registration Number:	0715343	SKELAXIN
Registration Number:	2168566	SONATA
Registration Number:	1772760	SYNERCID
Registration Number:	2396275	SYNERCID
Registration Number:	1652129	THEREVAC
Registration Number:	2044605	THROMBIN-JMI
Registration Number:	1393762	TUSSIGON
Registration Number:	1619385	VANEX-HD
Serial Number:	77148986	JMI
Serial Number:	77329426	KAIR
Serial Number:	77253473	KING ON DEMAND
Serial Number:	77384725	MIPEN
Serial Number:	77629777	OPTIMAL FORUM
Serial Number:	77612033	REMOXY (OXYCODONE CONTROLLED-RELEASE) CAPSULES
Serial Number:	77478874	REMOXY XRT
Serial Number:	77612057	REMOXY XRT (OXYCODONE CONTROLLED-RELEASE) CAPSULES EXTRACTION RESISTANT TECHNOLOGY
Serial Number:	77384765	SUMAJEX
Serial Number:	77384760	SUMAQUIX
Serial Number:	77103110	THROMBI-PAD
Serial Number:	77103099	THROMBI-PASTE
Serial Number:	77478862	XRT

CORRESPONDENCE DATA

Fax Number: (800)494-7512

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: (202) 370-4761

Email: ecallahan@nationalcorp.com

Correspondent Name: Elspeth Callahan

TRADEMARK
REEL: 004204 FRAME: 0022

Address Line 1: 1100 G St NW Suite 420
Address Line 2: National Corporate Research
Address Line 4: Washington, DISTRICT OF COLUMBIA 20005

ATTORNEY DOCKET NUMBER: F126672

NAME OF SUBMITTER: Mariee Pilkington

Signature: /Mariee Pilkington/

Date: 05/11/2010

Total Attachments: 4

source=T.Release - King Pharmaceuticals Research#page2.tif
source=T.Release - King Pharmaceuticals Research#page3.tif
source=T.Release - King Pharmaceuticals Research#page4.tif
source=T.Release - King Pharmaceuticals Research#page5.tif

Release of Security Interest in Trademarks

May 11, 2010

WHEREAS, King Pharmaceuticals, Inc., certain of its subsidiaries and Credit Suisse AG, Cayman Islands Branch (formerly Credit Suisse, Cayman Islands Branch) (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the “**GCA**”) dated December 29, 2008;

WHEREAS, pursuant to the GCA, Credit Suisse and King Pharmaceuticals Research and Development, Inc. (the “**Assignee**”) entered into that certain Trademark Security Agreement dated December 29, 2008 and recorded with the United States Patent and Trademark Office on December 30, 2008 on Reel No. 3911, Frame 0696 (the “**Trademark Security Agreement**”);

WHEREAS, under the Trademark Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Trademark Collateral (as defined in the Trademark Security Agreement), including those items set forth on Schedule 1 hereto (the “**Released Trademark Collateral**”); and

WHEREAS, Credit Suisse desires to release the security interest granted by the Assignee under the Trademark Security Agreement in the Released Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Trademark Security Agreement in the Released Trademark Collateral, together with all of the goodwill of the business connected with the use of, or symbolized by, such Released Trademark Collateral, and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee all right, title and interest of Credit Suisse in, to and under such Released Trademark Collateral and such goodwill granted under the Trademark Security Agreement. This Release of Security Interest in Trademarks shall be binding upon Credit Suisse’s legal representatives, assigns and successors and upon the Secured Parties. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Trademarks against the Released Trademark Collateral.

[signature page to follow]

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Trademarks to be duly executed by its officer thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN
ISLANDS BRANCH

By: 
Name: DOREEN BARR
Title: DIRECTOR

By: 
Name: VIPUL DHADDA
Title: ASSOCIATE

[signature page – King R&D trademark release]

Schedule 1**King Pharmaceuticals Research and Development, Inc.****TRADEMARKS**

Trademark	Registration #	Registration Date
ADENOCARD	1473847	January 26, 1988
ADENOSCAN	1816335	January 11, 1994
ADENOSCAN	1541189	May 30, 1989
ALTACE	1812659	December 21, 1993
AVINZA	2669786	December 31, 2002
AVINZA (Design)	3319329	October 23, 2007
CHLOROSTAT	1600325	June 12, 1990
CORGARD	1040408	June 1, 1976
CORZIDE	1170890	September 29, 1981
CYTOMEL	2167335	June 23, 1998
DP	3049183	January 24, 2006
DP and Design	1742709	December 29, 1992
Enema Design	1810413	December 14, 1993
LEVOXYL	2016089	November 12, 1996
Levoxyl Tablet Design	2158841	May 19, 1998
LIQUI-CHAR	1657982	September 24, 1991
PULMONAIRE	874778	August 12, 1969
REMOXY	3362798	January 1, 2008
SILVADENE	926416	January 4, 1972
SILVADENE	1020307	September 16, 1975
SKELAXIN	715343	May 16, 1961
SONATA	2168566	June 23, 1998
SYNERCID	1772760	May 25, 1993
SYNERCID and Design	2396275	October 17, 2000
THEREVAC	1652129	July 30, 1991
THROMBIN-JMI	2044605	March 11, 1997
TUSSIGON	1393762	May 20, 1986
VANEX-HD	1619385	October 30, 1990

TRADEMARK APPLICATIONS

Trademark Application	Application #	Application Date
JMI	77/148986	April 4, 2007
KAIR	77/329426	November 14, 2007
KING ON DEMAND	77/253473	August 13, 2007
MIPEN	77/384725	January 30, 2008
OPTIMAL FORUM	77/629777	December 9, 2008
REMOXY and Design	77/612033	November 11, 2008
REMOXY XRT	77/478874	May 20, 2008
REMOXY XRT and Design	77/612057	November 11, 2008
SUMAJEX	77/384765	January 30, 2008
SUMAQUIX	77/384760	January 30, 2008
THROMBI-PAD	77/103110	February 8, 2007
THROMBI-PASTE	77/103099	February 8, 2007
XRT	77/478862	May 20, 2008

TRADEMARK LICENSES

Name of Agreement	Parties Licensor/Licensee	Date of Agreement	Subject Matter
License, Development and Commercialization Agreement	Acura Pharmaceuticals, Inc./ King Pharmaceuticals Research and Development, Inc.	October 30, 2007	Acurox and follow-on products
Assignment, Assumption and Consent Agreement	Elan Pharma International Limited and Elan Management Limited/King Pharmaceuticals Inc. and King Pharmaceuticals Research and Development, Inc.	February 26, 2007	Avinza
Bill of Sale and Assignment and Assumption Agreement	Ligand Pharmaceuticals, Inc./ King Pharmaceuticals Research and Development, Inc.	February 26, 2007	Avinza
Asset Purchase Agreement	Allerex Laboratory Ltd., Anna Maria Solinas Laroche, Rita Fraser, 1055733 Ontario Limited/ King Pharmaceuticals Research and Development, Inc. and 6494871 Canada Ltd.	March 1, 2006	Epi-Pen
Amended and Restated Asset Purchase Agreement	Elan Corporation, plc, Elan Pharma International Limited, Elan Pharmaceuticals, Inc./King Pharmaceuticals, Inc., Jones Pharma Incorporated, and Monarch Pharmaceuticals, Inc.	May 19, 2003	Skelaxin